StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Friday morning. The firm issued a sell rating on the stock.

NSPR has been the topic of several other research reports. Piper Sandler reiterated an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research note on Tuesday, September 17th. Lake Street Capital began coverage on shares of InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 price target on the stock.

InspireMD Stock Up 0.7 %

NSPR opened at $3.00 on Friday. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.42. The firm has a 50 day moving average price of $2.69 and a 200-day moving average price of $2.69. The stock has a market capitalization of $78.25 million, a price-to-earnings ratio of -4.00 and a beta of 0.98.

InspireMD (NYSE:NSPR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The firm had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same period last year, the business posted ($0.15) EPS. As a group, analysts expect that InspireMD will post -0.79 earnings per share for the current year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC purchased a new position in InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD at the end of the most recent quarter. 44.78% of the stock is currently owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.